AlphaMark Advisors LLC Makes New Investment in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

AlphaMark Advisors LLC acquired a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 5,675 shares of the biopharmaceutical company’s stock, valued at approximately $325,000.

Other hedge funds have also made changes to their positions in the company. One Wealth Advisors LLC acquired a new position in Halozyme Therapeutics in the 3rd quarter valued at approximately $206,000. Creative Planning raised its stake in shares of Halozyme Therapeutics by 25.6% in the third quarter. Creative Planning now owns 46,834 shares of the biopharmaceutical company’s stock valued at $2,681,000 after purchasing an additional 9,543 shares in the last quarter. Novare Capital Management LLC acquired a new stake in shares of Halozyme Therapeutics during the 3rd quarter worth about $272,000. Oliver Luxxe Assets LLC bought a new position in Halozyme Therapeutics during the 3rd quarter valued at about $1,590,000. Finally, Redhawk Wealth Advisors Inc. boosted its position in Halozyme Therapeutics by 3.2% in the third quarter. Redhawk Wealth Advisors Inc. now owns 36,768 shares of the biopharmaceutical company’s stock valued at $2,105,000 after buying an additional 1,155 shares in the last quarter. Institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Price Performance

Halozyme Therapeutics stock opened at $52.61 on Friday. The business’s 50-day simple moving average is $58.69 and its 200 day simple moving average is $51.14. The company has a quick ratio of 6.21, a current ratio of 7.41 and a debt-to-equity ratio of 5.19. The stock has a market cap of $6.70 billion, a price-to-earnings ratio of 21.74, a P/E/G ratio of 0.49 and a beta of 1.27. Halozyme Therapeutics, Inc. has a 12-month low of $32.83 and a 12-month high of $65.53.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.73 by $0.18. The company had revenue of $231.40 million for the quarter, compared to analyst estimates of $204.94 million. Halozyme Therapeutics had a net margin of 38.62% and a return on equity of 195.80%. The company’s revenue for the quarter was up 4.7% on a year-over-year basis. During the same quarter last year, the firm earned $0.68 EPS. As a group, research analysts anticipate that Halozyme Therapeutics, Inc. will post 3.71 earnings per share for the current year.

Wall Street Analyst Weigh In

HALO has been the subject of several recent analyst reports. Wells Fargo & Company lowered shares of Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and raised their price objective for the stock from $58.00 to $62.00 in a report on Monday, October 7th. Cowen reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a report on Friday. The Goldman Sachs Group boosted their price objective on Halozyme Therapeutics from $44.00 to $49.00 and gave the stock a “neutral” rating in a research note on Monday, July 22nd. Benchmark restated a “buy” rating and issued a $60.00 target price on shares of Halozyme Therapeutics in a research note on Thursday, August 8th. Finally, JPMorgan Chase & Co. cut Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and lifted their price target for the company from $52.00 to $57.00 in a report on Thursday, September 19th. Four equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $60.44.

Insiders Place Their Bets

In other news, SVP Michael J. Labarre sold 10,000 shares of the stock in a transaction on Wednesday, October 16th. The stock was sold at an average price of $53.26, for a total value of $532,600.00. Following the transaction, the senior vice president now owns 173,756 shares of the company’s stock, valued at $9,254,244.56. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the stock in a transaction dated Wednesday, October 16th. The stock was sold at an average price of $53.26, for a total value of $532,600.00. Following the transaction, the senior vice president now owns 173,756 shares of the company’s stock, valued at approximately $9,254,244.56. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Matthew L. Posard sold 9,881 shares of the firm’s stock in a transaction dated Wednesday, August 14th. The stock was sold at an average price of $57.70, for a total value of $570,133.70. Following the transaction, the director now owns 69,874 shares in the company, valued at approximately $4,031,729.80. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 104,881 shares of company stock valued at $5,990,684. Company insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.